Nolan P E, Marcus F I, Erstad B L, Hoyer G L, Furman C, Kirsten E B
Department of Pharmacy Practice, College of Pharmacy, University of Arizona, Tucson 85721.
J Clin Pharmacol. 1989 Jan;29(1):46-52. doi: 10.1002/j.1552-4604.1989.tb03236.x.
Previous reports have suggested an interaction between propafenone and digoxin. We investigated the pharmacokinetics of IV digoxin when given alone (Phase I), after pretreatment with propafenone 150 mg every 8 hours for seven days (Phase II), and after propafenone 300 mg every 8 hours for 7 days (Phase III). The total body clearance of digoxin during Phase I was 2.45 ml/min/kg and was 2.17 ml/min/kg during Phase II (NS) and decreased to 1.92 ml/min/kg during Phase III (P less than 0.05). The renal clearance and half-life of digoxin were not significantly altered by propafenone. There was a trend towards a decrease in the volume of distribution of digoxin from 9.43 L/kg in Phase I, to 9.33 L/kg in Phase II, and 8.02 L/kg in Phase III. Similarly there was a trend towards a decreased nonrenal clearance of digoxin from 1.21 ml/min/kg during Phase I to 1.01 ml/min/kg during Phase II and to 0.75 ml/min/kg during Phase III. The changes in volume of distribution and nonrenal clearance parallel each other resulting in no change in the elimination half-life of digoxin. It is postulated that the mechanism of this interaction is due to decreases in the volume of distribution and nonrenal elimination of digoxin by propafenone. The degree of this interaction was related to the dose of propafenone. The magnitude of this interaction may be greater in patients and, thus, may require a reduction in the digoxin dose.
先前的报告提示普罗帕酮与地高辛之间存在相互作用。我们研究了静脉注射地高辛在单独给药时(I期)、每8小时给予150 mg普罗帕酮预处理7天后(II期)以及每8小时给予300 mg普罗帕酮7天后(III期)的药代动力学。I期地高辛的总体清除率为2.45 ml/min/kg,II期为2.17 ml/min/kg(无统计学差异),III期降至1.92 ml/min/kg(P<0.05)。普罗帕酮未显著改变地高辛的肾清除率和半衰期。地高辛的分布容积有从I期的9.43 L/kg降至II期的9.33 L/kg以及III期的8.02 L/kg的趋势。同样,地高辛的非肾清除率也有从I期的1.21 ml/min/kg降至II期的1.01 ml/min/kg以及III期的0.75 ml/min/kg的趋势。分布容积和非肾清除率的变化相互平行,导致地高辛的消除半衰期无变化。据推测,这种相互作用的机制是由于普罗帕酮使地高辛的分布容积和非肾清除减少。这种相互作用的程度与普罗帕酮的剂量有关。这种相互作用在患者中可能更大,因此可能需要减少地高辛的剂量。